Background
Obstructive sleep apnoea (OSA) is common. Medicare Benefits Schedule rules regarding which patients are eligible for a sleep study without first needing to see a sleep or respiratory specialist have recently changed and incorporate validated questionnaires of OSA risk and subjective sleepiness.
Objective
The aim of this article is to bring general practitioners (GPs) up to date with the key factors that should be assessed when considering whether a patient has OSA. It also highlights the strengths and weaknesses of the screening questionnaires, and the pros and cons of different types of sleep studies.
Discussion
OSA may significantly affect quality of life, mood, safety and cardiovascular risk. Assessment should focus on symptoms. Screening questionnaires have high sensitivity but, when used alone, poor specificity for moderate-tosevere OSA. The Epworth Sleepiness Scale (ESS) is a poor marker of OSA but does predict response to treatment when elevated. GPs can directly order sleep studies when OSA questionnaires are positive and the ESS is elevated; however, negative questionnaires do not exclude OSA or another sleep disorder.
OBSTRUCTIVE SLEEP APNOEA (OSA) is the repetitive collapse of the upper airway during sleep. The collapse is either complete, leading to cessation of airflow (apnoea), or partial, leading to a reduction in airflow (hypopnoea). Partial collapse is more common. The severity of OSA is usually determined by the frequency of obstructive respiratory events and defined by the Apnoea Hypopnoea Index (AHI), which is the average number of respiratory disturbances per hour of sleep. OSA has been arbitrarily defined as an AHI ≥5 events/hour, and moderate-to-severe OSA is defined as an AHI ≥15 events/ hour. 1 The prevalence of OSA is very high in the general adult population, with figures as high as 38%, depending on the population studied and definition used. 2 Much of this OSA is mild in severity (AHI between 5-15 events/ hour) and minimally symptomatic. Although not associated with adverse vascular sequelae, mild OSA may still be associated with troublesome daytime symptoms in some subjects. Moderateto-severe OSA (AHI ≥15 events/ hour) is more commonly symptomatic and is associated with other adverse outcomes such as cardiovascular and cerebrovascular disease, cognitive decline, motor vehicle accidents and depression. It is also very common, being found in 6-17% of the general adult population, with a recent Australian study showing a prevalence of 8.3%. 3, 4 In general, both mild OSA plus daytime symptoms and moderate-to-severe OSA are indications to consider OSA treatment.
Given the high prevalence of OSA in the general adult population, a large number of patients presenting to general practitioners (GPs) will have OSA. Known risk factors include obesity, adenotonsillar hypertrophy (mainly seen in children and young adults), increasing age, type 2 diabetes, alcohol and sedative use, and hypertension that is difficult to control. 5, 6 Because many patients with OSA may be minimally symptomatic, it is unclear whether there are overall benefits to widespread screening of either the general population or high-risk individuals (eg those with type 2 diabetes). A recent review of the literature by the US Preventive Services Task Force has concluded that there is insufficient evidence to support screening for OSA in otherwise asymptomatic individuals. 7, 8 Nevertheless, a large number of patients presenting to GPs will have symptoms of OSA, and it is important to consider 'trigger symptoms' that warrant further assessment of OSA risk and determination of the need for sleep testing. 
OSA symptoms

Clinical assessment
As well as asking about symptoms related to OSA in the clinical assessment, it is important to consider a number of other factors that may affect the diagnostic and treatment pathway. These include the following.
• Signs of adenotonsillar hypertrophy.
Although less common with increasing age, this is important as it points to a potential surgical treatment for OSA.
• Driving and workplace safety. If OSA is suspected in commercial drivers or other safety-critical workers -or if there are symptoms of sleepiness while driving -assessment for OSA (or another sleep disorder) should be undertaken urgently and advice about driving risk provided.
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• Obesity. This is the major reversible risk factor for OSA, and OSA symptoms commonly develop in conjunction with a period of rapid weight gain. 10 This is an opportune time to address the obesity and its associated cardiometabolic risks.
• Hypertension. OSA is associated with hypertension, and continuous positive airway pressure (CPAP) treatment may improve blood pressure control, particularly if the OSA is severe or the hypertension is treatmentresistant.
6,11
• Depression. This commonly co-exists with OSA and shares similar symptoms of tiredness, fatigue, sleepiness and poor motivation. Depression is also a risk factor for an incomplete response to CPAP treatment and may need to be independently addressed.
OSA screening questionnaires Berlin Questionnaire
The first screening questionnaire for OSA that was designed specifically for use in general practice was the Berlin Questionnaire (BQ). 12 The BQ was a consensus outcome following a conference on sleep in primary care held in Berlin, Germany, in 1996 that was attended by US and German respiratory and primary care physicians. The BQ consists of 11 items within three different categories that ask about:
• snoring and witnessed apneas (category 1)
• daytime sleepiness or fatigue (category 2)
• self-reported hypertension and obesity (body mass index [BMI]; category 3). Patients are then classified as either high risk or low risk for OSA. In a meta-analysis of BQ performance for predicting a diagnosis of moderateto-severe OSA (defined as an AHI ≥15 events/hour), there was a sensitivity (ie proportion of patients with OSA who had a positive test) of 82%, and a specificity (ie proportion of patients without OSA who had a negative test) of 39%.
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OSA50 questionnaire
The OSA50 questionnaire (Table 1) was developed by a group of Australian sleep medicine researchers who aimed to create a brief, four-item OSA screening tool for use in general practice.
14 They established that the four items that best predicted a diagnosis of severe OSA (ie AHI ≥30 events/hour) were: 1. obesity (by waist circumference) 2. snoring 3. witnessed apneas 4. age ≥50 years. Weightings from results of logistic regression analyses were used to create a simple screening tool with a maximum score of 10 points. An OSA50 score ≥5 points was found in a validation sample to have 94% sensitivity, with 31% specificity for identifying moderate-to-severe OSA.
STOP-BANG questionnaire
The STOP-BANG questionnaire (www. stopbang.ca/osa/screening.php) was developed by an anaesthetist from Toronto, Canada, and was originally validated for use in a pre-operative, 6 . age >50 years 7. neck circumference >40 cm 8. male gender. High risk for OSA is defined as a positive response to ≥3 items. A potential advantage of the STOP-BANG questionnaire is that different cut-off scores can be used to trade off sensitivity and specificity. For example, using a higher cut-off score reduces the sensitivity but increases the specificity of the STOP-BANG questionnaire. 16 This means a higher cut-off will miss more cases of OSA when negative, but a positive result will be more likely to be a true positive. This is highly relevant when considering the MBS item number rules, which specify that a cut-off score of ≥4 be used.
Performance of OSA screening questionnaires
OSA screening questionnaires at recommended cut-off points tend to have high sensitivity but poor specificity (Table 2) ; in other words, while the majority of patients who have OSA will screen positive, there will be a large number of false-positive results. 13, 14, 16 Therefore, screening questionnaires alone are inadequate for confirming a diagnosis, and patients who have a positive screening test should proceed to further evaluation with formal sleep study testing to confirm the presence or absence of OSA.
Surprisingly, very few studies have assessed the performance of the questionnaires in primary care populations. Ongoing Australian research suggests that the sensitivity in primary care is lower than in other selected populations. This means that a negative screening questionnaire does not rule out OSA (or any alternative sleep disorder), and referral to a sleep medicine specialist is recommended if there is ongoing doubt.
These questionnaires have not been validated in children and should only be used in adults.
Epworth Sleepiness Scale
The Epworth Sleepiness Scale (ESS) provides a subjective measure of daytime sleepiness by asking the patient to rate their chance of dozing off (score of 0-3) in eight commonly encountered scenarios to provide a score out of 24, with higher scores indicating greater degrees of daytime sleepiness. 17 An ESS score ≥8 suggests the presence of at least mild daytime sleepiness. 18 Of critical importance, the ESS score does not correlate well with AHI, as not all patients with OSA will have symptoms of sleepiness detected by the ESS and there are multiple causes for excessive daytime sleepiness beyond OSA (eg other sleep disorders, depression). Therefore, the ESS should not be used alone as a screening tool to identify patients at high risk of OSA. When used in conjunction with an OSA screening questionnaire, the ESS is likely to be helpful in identifying patients at high risk of symptomatic disease who will benefit from treatment. However, this remains the subject of ongoing research and it is important to realise that the majority of patients with OSA will not have an ESS ≥8. 19, 20 Medicare Benefits Schedule rules regarding primary care referral pathways for sleep studies The aim is to allow GPs to expedite diagnosis and treatment in a highly symptomatic group of patients with OSA; however, it is important to realise that many patients with significant OSA will not meet this questionnaire combination. These patients will need assessment by sleep or respiratory medicine specialists. Refer to Figure 1 for potential investigation pathways. 
Types of sleep studies
The gold standard test for diagnosing OSA is with in-laboratory full polysomnography (PSG) with a sleep technician in attendance throughout the night. However, in-laboratory PSG is limited in its availability, labour intensive and costly, so increasing attention has been focused on home sleep study testing. Traditionally, sleep studies have been divided into the following four categories:
• Type 1: Attended, in-laboratory, full PSG with ≥7 recording channels measuring sleep stage, breathing and cardiac parameters, and limb movements.
• Type 2: Unattended, home, full PSG with ≥7 recording channels.
• Type 3: Limited channel monitoring of breathing parameters without sleep assessment.
Patient presents with symptoms suspicious for OSA.
Monitor symptoms, CPAP adherence, treatment response.
Questionnaire negative, ESS ≥8
Consider other sleep disorders, mood disorders and sleep specialist referral. (ie high pretest probability of OSA)
Direct referral for diagnostic PSG:
• Level 2 home or Level 1 in-lab where home study not suitable.
• Level 3 or 4 study may be acceptable depending on local resources (eg rural setting).
• ASA/NATA-accredited laboratory recommended but not mandatory.
Moderate-to-severe OSA on PSG (AHI >15) or mild OSA with significant symptoms and with no major comorbidities, driving risk (refer sleep specialist if latter present)
GP-guided OSA treatment, provided skilled in this with access to specialist support:
Implement treatment with lifestyle measures and CPAP. Consider dental or surgical referral where appropriate. Manage cardiovascular and metabolic comorbidities. Results from home PSG (type 2) testing have been shown to have a high level of agreement when compared with in-laboratory PSG for the diagnosis of OSA, although there is greater potential for signal loss and study failure (~7%) due to the lack of an attending sleep technician. 21, 22 While home PSG testing is likely to be appropriate for many patients with a suspected diagnosis of OSA, some patients should undergo attended, in-laboratory (type 1) PSG testing. 23 Factors that may make home sleep studies unsuitable for some patients include the following: 
Conclusion
OSA is a treatable, common disease presenting to GPs. Untreated, it may have major adverse impacts on health. An initial clinical assessment, which includes validated questionnaires, helps triage patients to sleep testing pathways that have now become embedded in the MBS. Despite their ability to recognise some patients with sleepiness and a high likelihood of OSA who can proceed to expedited sleep testing, it is important to note that negative questionnaires (particularly the ESS) do not rule out patients having clinically significant OSA. These patients will need specialist referral.
